Clicky

Swedish Orphan Biovitrum AB (publ)(B6E) News

Date Title
Jun 6 Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases
Jun 6 Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
Jun 4 Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025
Jun 3 Invitation: Sobi's Aspaveli® - 52-week Phase 3 VALIANT data in nephrology
Apr 15 Invitation: Sobi's Q1 report
Apr 1 Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Mar 31 Sobi publishes Annual and sustainability report for 2024
Feb 20 EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
Feb 20 Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN